Martina Pennisi

Fondazione IRCCS Istituto Nazionale dei Tumori — Italy

Medicine · Health Sciences

21h-index2.2kcitations108works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(75), Lymphoma Diagnosis and Treatment(26), Integrated Circuits and Semiconductor Failure Analysis(14), Immunotherapy and Immune Responses(13), Advancements in Semiconductor Devices and Circuit Design(12)

Publications108 total

Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study
Transplantation and Cellular Therapy·2026Open Access
Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study
Blood·2025
Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study
Blood·2025
Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort
Blood·2025Open Access
A survey on the practices and the management of hemorrhagic cystitis in patients who undergo allogeneic hematopoietic stem cell transplantation, on behalf of the Infectious Diseases Working Party of EBMT
Bone Marrow Transplantation·2025Open Access
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma
Blood Advances·2025· 1 citedOpen Access
Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
British Journal of Haematology·2025· 1 citedOpen Access
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study
Transplantation and Cellular Therapy·2025
314 | ISOLATED CENTRAL NERVOUS SYSTEM RELAPSE AFTER CAR‐T CELL INFUSION IN LARGE B‐CELL LYMPHOMAS: AN ANALYSIS FROM THE ITALIAN CART‐SIE STUDY
Hematological Oncology·2025Open Access
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma
Transplantation and Cellular Therapy·2025· 8 cited
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study
Transplantation and Cellular Therapy·2025· 4 citedOpen Access
Brexucabtagene autoleucel in‐vivo expansion and <scp>BTKi</scp> refractoriness have a negative influence on progression‐free survival in mantle cell lymphoma: Results from <scp>CART</scp>‐<scp>SIE</scp> study
British Journal of Haematology·2024· 6 citedOpen Access
EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy
Scientific Reports·2024· 3 citedOpen Access
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma
Leukemia & lymphoma/Leukemia and lymphoma·2024· 1 citedOpen Access
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Retrospective Multicenter Analysis on 285 Procedures Performed between 2000 and 2020
Blood·2024
Supplementary Table 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024Open Access
Supplementary Figure 1 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024Open Access
Supplementary Figure 3 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024Open Access
Supplementary Table 4 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024Open Access
Supplementary Table 5 from A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas
2024Open Access
page 1 of 6Next →

Frequent Co-authors

Miguel‐Angel Perales(25), Paolo Corradini(21), Sean M. Devlin(14), Molly Maloy(13), Tania Jain(12), Gunjan L. Shah(12), Michael Scordo(12), Craig S. Sauter(12), Elena Mead(12), Connie Lee Batlevi(12), Anna Dodero(12), Anna Guidetti(12), Parastoo B. Dahi(11), Annalisa Chiappella(11), Josel D. Ruiz(10), Sergio Giralt(10), Bianca Santomasso(10), Silva Ljevar(9), Jae H. Park(8), Maria Lia Palomba(8)